George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
News|Articles|November 19, 2023
Rheumatoid Arthritis Quiz: Inclusion of Minorities in Clinical Trials
Author(s)Ingrid Torjesen
Some racial minority groups face higher disease burdens and worse outcomes in rheumatoid arthritis, so it is important to ensure that clinical trials include representatives from these groups. Take this quiz to test your knowledge of efforts to ensure minorities are represented in clinical trials.
Advertisement
Which racial group(s) have been shown to be underrepresented in trials of drugs for rheumatoid arthritis?
Advertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles
5